Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (171-180 of 393) with videos related to

Pageof 40
Sort By:
JAMA Dermatology|June 7, 2018
Identifying a Core Domain Set to Assess Psoriasis in Clinical TrialsKristina Callis Duffin, Joseph F Merola, Robin Christensen, et al.
JAAD Case Reports|September 27, 2021
Disseminated varicella-zoster virus infections following messenger RNA-based COVID-19 vaccinationJordan Taylor Said, Cesar A Virgen, Christine G Lian, et al.
Journal of the American Academy of Dermatology|March 21, 2021
Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitisJoseph F Merola, Jerry Bagel, Peter Almgren, et al.
The Journal of Dermatological Treatment|April 6, 2022
Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studiesPeter C Taylor, Andrew G Bushmakin, Joseph C Cappelleri, et al.
Journal of the American Academy of Dermatology|February 26, 2022
Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic reviewJordan Taylor Said, Scott Andrew Elman, Lourdes Maria Perez-Chada, et al.
Journal of the American Academy of Dermatology|March 11, 2023
Use of systemic immunomodulating medications in pregnant women with atopic dermatitis: A nationwide US studyKatharina Schoder, Yanmin Zhu, Sebastian Schneeweiss, et al.
JAMA Dermatology|June 2, 2021
Use of Tofacitinib, 2%, Ointment for Periorbital Discoid Lupus ErythematosusDaniel R Mazori, Michelle S Min, Bina Kassamali, et al.
Rheumatology (Oxford, England)|October 18, 2024
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trialArthur Kavanaugh, Laura C Coates, Philip J Mease, et al.
Journal of the American Academy of Dermatology|April 6, 2021
The catch-22 of limited Food and Drug Administration approval for connective tissue disease therapiesMichelle S Min, Bina Kassamali, Daniel R Mazori, et al.
Arthritis Care & Research|May 11, 2021
Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic ArthritisYinzhu Jin, Hemin Lee, Moa P Lee, et al.
Pageof 40

Showing results (171-180 of 393) with videos related to

Sort By:
Pageof 40
JAMA Dermatology|June 7, 2018
Identifying a Core Domain Set to Assess Psoriasis in Clinical TrialsKristina Callis Duffin, Joseph F Merola, Robin Christensen, et al.
JAAD Case Reports|September 27, 2021
Disseminated varicella-zoster virus infections following messenger RNA-based COVID-19 vaccinationJordan Taylor Said, Cesar A Virgen, Christine G Lian, et al.
Journal of the American Academy of Dermatology|March 21, 2021
Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitisJoseph F Merola, Jerry Bagel, Peter Almgren, et al.
The Journal of Dermatological Treatment|April 6, 2022
Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studiesPeter C Taylor, Andrew G Bushmakin, Joseph C Cappelleri, et al.
Journal of the American Academy of Dermatology|February 26, 2022
Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic reviewJordan Taylor Said, Scott Andrew Elman, Lourdes Maria Perez-Chada, et al.
Journal of the American Academy of Dermatology|March 11, 2023
Use of systemic immunomodulating medications in pregnant women with atopic dermatitis: A nationwide US studyKatharina Schoder, Yanmin Zhu, Sebastian Schneeweiss, et al.
JAMA Dermatology|June 2, 2021
Use of Tofacitinib, 2%, Ointment for Periorbital Discoid Lupus ErythematosusDaniel R Mazori, Michelle S Min, Bina Kassamali, et al.
Rheumatology (Oxford, England)|October 18, 2024
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trialArthur Kavanaugh, Laura C Coates, Philip J Mease, et al.
Journal of the American Academy of Dermatology|April 6, 2021
The catch-22 of limited Food and Drug Administration approval for connective tissue disease therapiesMichelle S Min, Bina Kassamali, Daniel R Mazori, et al.
Arthritis Care & Research|May 11, 2021
Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic ArthritisYinzhu Jin, Hemin Lee, Moa P Lee, et al.
Pageof 40